CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Favipiravir (3600 mg + 1600 mg)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)


Name (Synonyms) Correlation
drug1121 Hydroxychloroquine combined with Azithromycin Wiki 1.00
drug924 Favipiravir (3200 mg + 1200 mg) Wiki 1.00
drug926 Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine Wiki 1.00
drug925 Favipiravir (3200 mg + 1200 mg) combined with Azithromycin Wiki 1.00
drug2765 blood sample Wiki 0.41
drug1086 Hydroxychloroquine Wiki 0.10

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D004630 Emergencies NIH 0.19
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

This is an open-label, multicenter, parallel-group, randomized, phase III trial that evaluates the efficacy and safety of hydroxychloroquine and favipiravir in the treatment of patients with possible or confirmed COVID-19 observed within the last 5 days. 1000 patients will be randomized in 2:1:2:2:2:1 ratio and divided into six groups.

NCT04411433 Sars-CoV2 COVID-19 Drug: Favipiravir (3200 mg + 1200 mg) Drug: Favipiravir (3600 mg + 1600 mg) Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin Drug: Hydroxychloroquine Drug: Hydroxychloroquine combined with Azithromycin

Primary Outcomes

Description: The evaluation of recovery (discharge) period until 14th day after administration.

Measure: Time to recovery (discharge)

Time: 14 days

Description: The evaluation of decrease in viral load until 14th day after administration.

Measure: Decrease in viral load

Time: 14 days

Secondary Outcomes

Description: Number/characteristics of Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment due to study drug from baseline until the end of study

Measure: Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment

Time: 14 days

Description: Clinical evaluation of occurrence of lymphopenia from baseline until the end of study.

Measure: Frequency of occurrence of lymphopenia from baseline

Time: 14 days

Description: Clinical evaluation of occurrence of thrombocytopenia from baseline until the end of study.

Measure: Frequency of occurrence of thrombocytopenia from baseline

Time: 14 days

Description: Clinical evaluation of ALT levels from baseline until the end of study.

Measure: Changes in alanine aminotransferase (ALT) levels from baseline

Time: 14 days

Description: Clinical evaluation of AST levels from baseline until the end of study.

Measure: Changes in aspartate aminotransferase (AST) levels from baseline

Time: 14 days

Description: Clinical evaluation of CRP levels from baseline until the end of study.

Measure: Changes in C-reactive protein (CRP) levels from baseline

Time: 14 days

Description: Clinical evaluation of D-dimer levels from baseline until the end of study.

Measure: Changes in level of D-dimer levels from baseline

Time: 14 days

Description: Clinical evaluation of PT values for blood to coagulate from baseline until the end of study.

Measure: Changes in prothrombin time (PT) values from baseline

Time: 14 days

Description: Clinical evaluation of PTT values for blood to coagulate from baseline until the end of study.

Measure: Changes in partial thromboplastin time (PTT) values from baseline

Time: 14 days

Description: Clinical evaluation of systolic and diastolic blood pressure levels from baseline until the end of study.

Measure: Changes in blood pressure from baseline

Time: 14 days

Description: Clinical evaluation of respiratory rate levels from baseline until the end of study.

Measure: Changes in respiratory rate from baseline

Time: 14 days

Description: Clinical evaluation of pulse oxymetry levels from baseline until the end of study.

Measure: Changes in pulse oxymetry from baseline

Time: 14 days

Description: Clinical evaluation of changes in fever from baseline until the end of study.

Measure: Changes in fever from baseline

Time: 14 days


No related HPO nodes (Using clinical trials)